8-K: Amwell Reports Q4 and Full Year 2023 Results, Provides 2024 Guidance and Path to Profitability

Amwell announced its fourth quarter and full year 2023 financial results, highlighting progress on its new platform and providing financial guidance for 2024 and 2025.

Summary

• Amwell reported a total revenue of $70.7 million for the fourth quarter of 2023, with subscription revenue at $27.3 million and Amwell Medical Group (AMG) visit revenue at $32.1 million.
• The company's gross margin for the quarter was 34%, and they experienced a net loss of $50.0 million, which is an improvement compared to the $137.1 million loss in the previous quarter, which included a $78.9 million non-cash goodwill impairment charge.
• Adjusted EBITDA for the fourth quarter was a loss of $36.9 million, compared to a loss of $38.5 million in the third quarter of 2023.
• For the full year 2023, Amwell's total revenue was $259.0 million, with subscription revenue at $112.4 million and AMG visit revenue at $119.5 million.
• The full year gross margin was 37%, and the net loss was $679.2 million, which includes a $436.5 million non-cash goodwill impairment charge, compared to a $272.1 million loss in 2022.
• Adjusted EBITDA for the full year was a loss of $165.4 million, compared to a loss of $175.3 million in 2022.
• Amwell had 103,000 active providers and 1.6 million total visits in the fourth quarter, with 52% of visits on the Converge platform.
• Total visits for the full year were 6.3 million.
• The company's cash and short-term securities totaled approximately $372.0 million at the end of the year.
• Amwell provided 2024 guidance with revenue projected between $259 million and $269 million, AMG visits between 1.6 and 1.7 million, and adjusted EBITDA loss between $160 million and $155 million.
• Preliminary 2025 guidance projects revenue between $335 million and $350 million and adjusted EBITDA loss between $45 million and $35 million.
• The company aims to achieve adjusted EBITDA breakeven in 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive signs of progress with the Converge platform and cost-cutting measures, the significant net losses and the lack of profitability are concerning. The company's guidance for future revenue and EBITDA is positive, but the path to profitability is still uncertain.

Positives

• The company successfully migrated more than half of its volume onto the new Converge platform.
• There was a significant reduction in net loss in Q4 2023 compared to Q3 2023, from $137.1 million to $50.0 million.
• The company improved efficiency and put in place elements to transform its commercial organization.
• Amwell has a clear objective to reach adjusted EBITDA breakeven by 2026.
• The company has a strong cash position with approximately $372 million in cash and short-term securities.

Negatives

• The company reported a significant net loss of $679.2 million for the full year 2023.
• The company's adjusted EBITDA was a loss of $165.4 million for the full year 2023.
• The company is still operating at a loss and is not yet profitable.
• The company's revenue decreased from $277.190 million in 2022 to $259.047 million in 2023.

Risks

• The company's ability to successfully transition clients to the Converge platform without significant attrition is a risk.
• The company faces risks related to renewing and upselling its client base.
• The company's relationship with the Defense Health Agency (DHA) and the continuation of that relationship beyond July 2025 with comparable financial terms is a risk.
• The telehealth market is experiencing weak growth and increased volatility.
• The company faces risks related to adapting to rapid technological changes and increased competition.
• Changes in healthcare laws, regulations, or trends could impact the company's operations.
• The company faces risks related to complying with federal and state privacy regulations and potential cybersecurity breaches.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Amwell projects 2024 revenue between $259 million and $269 million, with an adjusted EBITDA loss between $160 million and $155 million. Preliminary 2025 guidance projects revenue between $335 million and $350 million and adjusted EBITDA loss between $45 million and $35 million. The company aims to achieve adjusted EBITDA breakeven in 2026.

Management Comments

• Ido Schoenberg, MD, chairman and CEO of Amwell, stated that 2023 was an important year for advancing goals in the digital healthcare market.
• He highlighted the securing and deployment of strategic clients, the successful migration of more than half of the volume onto the Converge platform, and improved efficiency within the company.
• He expressed high conviction regarding the company's path to profitability in 2024.

Industry Context

This announcement comes as the telehealth industry faces increased competition and scrutiny, with companies needing to demonstrate a clear path to profitability. Amwell's focus on its Converge platform and its efforts to improve efficiency are in line with the industry's need for scalable and cost-effective solutions. The company's guidance for 2024 and 2025 reflects the challenges and opportunities in the current market.

Comparison to Industry Standards

• Teladoc, a major competitor in the telehealth space, reported a revenue of $660.5 million in Q4 2023, significantly higher than Amwell's $70.7 million, but also reported a net loss of $292.7 million, indicating that profitability is a challenge across the industry.
• Similar to Amwell, other telehealth companies are also focusing on platform migrations and cost optimization to improve their financial performance.
• Amwell's gross margin of 34% in Q4 2023 is within the range of other telehealth companies, but there is a wide range of performance across the industry.
• The company's adjusted EBITDA loss of $36.9 million in Q4 2023 is a concern, but the company is projecting a path to profitability by 2026, which is a common goal for many companies in the sector.

Related Party Transactions

• The document mentions accounts receivable from related parties of $1,626 and $2,597 for 2023 and 2022 respectively.
• Deferred revenue from related parties was $1,286 and $1,665 for 2023 and 2022 respectively.

Stakeholder Impact

• Shareholders may be concerned about the significant net losses, but encouraged by the company's path to profitability.
• Employees may be impacted by the company's cost-cutting measures and commercial transformation.
• Customers may benefit from the improved Converge platform and the company's focus on efficiency.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to focus on transitioning clients to the Converge platform.
• Amwell will work to improve efficiency and transform its commercial organization.
• The company will continue to execute its plan to achieve adjusted EBITDA breakeven by 2026.
• Amwell will host a conference call to discuss its financial results.

Key Dates

Keywords

telehealth, digital health, hybrid care, virtual care, healthcare, SaaS, subscription revenue, EBITDA, financial results, Converge platform